<DOC>
	<DOCNO>NCT00528788</DOCNO>
	<brief_summary>Patients chronic kidney disease end stage renal disease great cardiovascular risk general population . Vitamin D analogues show observational study mortality benefit patient . This study design investigate doxercalciferol 's effect vasculature ( i.e . endothelial cell function ) possible mechanism explain mortality benefit .</brief_summary>
	<brief_title>How Vitamin D Analogues Affect Endothelial Cells Patients Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Stage 5 Chronic Kidney Disease Hyperparathyroidism ( PTH &gt; 300 ) require vitamin D therapy Age 1880 year old Ability provide inform consent Subjects neovascularization present , neoplasm , active wound significant retinopathy Subjects contraindication allergy vitamin D Subjects currently vitamin D therapy history vitamin D therapy previous 60 day Serum phosphorus &gt; 6 Serum calcium &gt; 10.5 contraindication nitroglycerin ( sildenafil )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>